v3.26.1
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Mar. 31, 2026
Nov. 04, 2025
Cash, Cash Equivalents, and Short-Term Investments $ 63,800   $ 61,000  
Accounts Receivable, Allowance for Credit Loss $ 0 $ 0    
Developed Technology Rights [Member] | Maximum [Member]        
Finite-Lived Intangible Asset, Useful Life (Year) 11 years 9 months      
Intellectual Property [Member]        
Finite-Lived Intangible Asset, Useful Life (Year) 20 years      
Customer Concentration Risk [Member] | Accounts Receivable [Member] | HHS Barda [Member]        
Concentration Risk, Percentage 98.00% 48.00%    
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Daiichi Sankyo [Member]        
Concentration Risk, Percentage   52.00%    
Customer Concentration Risk [Member] | Unbilled Receivables [Member] | HHS Barda [Member]        
Concentration Risk, Percentage 100.00% 100.00%    
Customer Concentration Risk [Member] | Research and Development [Member] | Clinical Research Organization and Analytical Testing Vendor [Member]        
Concentration Risk, Percentage 76.00%      
Customer Concentration Risk [Member] | Research and Development [Member] | Clinical Research Organization [Member]        
Concentration Risk, Percentage   18.00%    
License Agreement and Purchase Agreement [Member]        
License Agreement, Stock To Be Purchased, Per Share (in dollars per share)       $ 0.45
License Agreement, Proceeds To Be Received       $ 30,000